Anne m of dating salution
In addition, Aclaris has submitted a Marketing Authorization Application (MAA) for Eskata for the treatment of SKs in select countries in the European Union.
Seborrheic keratoses (SKs) are non-cancerous skin growths that affect more than 83 million Americans and are most commonly seen in middle-aged and older adults.
Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
As a clinician, I saw first-hand that patients preferred non-invasive treatments,” said Stuart D. “With the approval of Eskata, I am pleased to be able to offer my patients a topical treatment option that is well tolerated and can clear raised SKs with a low risk of scarring.” The FDA approval of Eskata is based on two pivotal Phase 3 trials that demonstrated the safety and efficacy of Eskata for the treatment of raised SKs.
In these trials, patients received up to two treatments with Eskata, with one at treatment initiation and a second at week three.
SKs are non-cancerous skin growths that affect more than 83 million American adults and can be an aesthetic skin concern. The condition is more prevalent than acne, psoriasis and rosacea combined.
“This achievement delivers on Aclaris’ commitment to bringing innovative therapies to market that address significant unmet needs in dermatology,” said Dr.